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PTHupregulates the expression of the receptor activator of nuclear factor !B ligand (Rankl) in cells
of the osteoblastic lineage, but the precise differentiation stage of the PTH target cell responsible
for RANKL-mediated stimulation of bone resorption remains undefined. We report that consti-
tutive activation of PTH receptor signaling only in osteocytes in transgenic mice (DMP1-caPTHR1)
was sufficient to increaseRanklexpressionandbone resorption.Resorption inDMP1-caPTHR1mice
crossedwithmice lacking thedistal control region regulatedbyPTH in theRanklgene (DCR!/!)was
similar to DMP1-caPTHR1 mice at 1 month of age, but progressively declined to reach values
undistinguishable from wild-type (WT) mice at 5 months of age. Moreover, DMP1-caPTHR1 mice
exhibited low tissuematerial density and increased serumalkaline phosphatase activity at 5month
of age, and these indices of high remodeling were partially and totally corrected in compound
DMP1-caPTHR1;DCR!/!malemice,and lessaffected in femalemice.Ranklexpression inbones from
DMP1-caPTHR1 mice was elevated at both 1 and 5 months of age, whereas it was high, similar
to DMP1-caPTHR1 mice at 1 month, but low, similar to WT levels at 5 months in compound mice.
Moreover, PTH increased Rankl and decreased Sost and Opg expression in ex vivo bone organ
cultures established from WT mice, but only regulated Sost and Opg expression in cultures from
DCR!/! mice. PTH also increased RANKL expression in osteocyte-containing primary cultures of
calvarial cells, in isolated murine osteocytes, and in WT but not in DCR!/! osteocyte-enriched
bones. Thus, PTH upregulates Rankl expression in osteocytes in vitro, ex vivo and in vivo, and
resorption inducedbyPTH receptor signaling in theadult skeleton requires direct regulationof the
Rankl gene in osteocytes. (Endocrinology 155: 2797–2809, 2014)
Accumulating evidence demonstrates that some ofthe actions of PTH on the skeleton are mediated by
direct effects of the hormone on osteocytes, the most
abundant and highly communicated cells in bone (1).
PTH downregulates the expression of the Sost gene,
which encodes the potent inhibitor of bone formation
sclerostin, expressed by osteocytes in bone (2, 3), and
also increases the expression of fibroblast growth factor
23 (Fgf23), a hormone expressed in osteocytes (and
osteoblasts) that regulates phosphate reabsorption
in the kidney, contributing to mineral homeostasis
(1, 4, 5).
Earlier studies have shown that the major skeletal ef-
fects of PTH are recapitulated in transgenic mice express-
ing a constitutively active PTH receptor in osteocytes,
named DMP1-caPTHR1 mice (1, 4, 6, 7). Bones from
these transgenic mice exhibit decreased Sost/sclerostin ex-
pression and elevatedWnt signaling, increasedosteoblasts
and bone formation, and a remarkable increase in bone
mineral density (BMD) in both the axial and appendicular
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skeletons (6, 7). DMP1-caPTHR1 mice also exhibit high
bone resorption, as evidenced by elevated resorption
markers in thebloodandurine, highnumberofosteoclasts
in bone, and elevated cortical porosity. Bones from
DMP1-caPTHR1 mice display an increased receptor ac-
tivator of NF-!B ligand (Rankl)/Opg ratio and elevated
macrophage colony-stimulating factor (M-Csf) expres-
sion. The elevated bone formation and increased bone
mass in DMP1-caPTHR1 mice are abolished by overex-
pressing Sost in osteocytes, demonstrating that the in-
crease in osteoblasts is due to reduced sclerostin expres-
sion unleashing Wnt signaling (6, 7). On the other hand,
increased osteoclast numbers and resorption are not elim-
inated by Sost overexpression. Taken together, these find-
ings demonstrate that PTH receptor signaling in osteo-
cytes regulates bone formation and resorption by distinct
mechanisms.
The pro-osteoclastogenic actions of PTH are long rec-
ognized to be associated with upregulation of Rankl and
downregulation ofOpg. However, the precise differenti-
ation stage of the PTH target cell that supports osteoclas-
togenesis remains undefined. Osteocytes express high lev-
els of Rankl and Opg compared with other osteoblastic
cells (8–10) and also expressM-Csf (11, 12). In addition,
deletion of theRankl gene from osteocytes leads to osteo-
petrosis in mice (9, 10). These pieces of evidence raise the
possibility that elevated resorption driven by PTH recep-
tor activation in osteocytes could result from direct regu-
lation of osteoclastogenic genes in these cells. By taking
advantage of the genetic model of osteocyte-driven bone
resorption induced by PTH receptor signaling (DMP1-
caPTHR1mice), we show in this study that removal of the
distal control region (DCR)of theRankl gene regulated by
PTHgradually corrects the increased resorption exhibited
byDMP1-caPTHR1mice andblunts the highRankl levels
inbone. Inaddition, PTHupregulatedRankl expression in
authentic osteocytes, in primary cultures of bone cells con-
taining osteocytes, and in bone organ cultures established
from wild-type (WT) mice; however, it fails to do so in
cultures established fromDCR!/!mice. These data show
that PTH receptor signaling in osteocytes enhances re-
sorption by regulating the expression of the Rankl gene
directly in osteocytes.
Materials and Methods
Generation of experimental mice
Experimental animals were generated by a 2-step breeding
strategy using transgenic mice expressing a constitutively active
PTHR1 in osteocytes under the control of the 8-kb fragment of
the promoter of the dentin matrix protein 1 gene (DMP1-
caPTHR1) (6) and knock-in mice lacking the distant transcrip-
tional enhancer region in the Rankl gene (DCR!/!) (13).
Heterozygous DMP1-caPTHR1 mice were crossed with DCR!/!
mice, and the resulting DMP1-caPTHR1;DCR!/! mice were
subsequently crossed with DCR!/! mice. Littermates of the 4
generated genotypeswere used for the experiments:WT,DMP1-
caPTHR1, DCR!/!, and compound DMP1-caPTHR1;
DCR!/! mice. All mice were born at the expected Mendelian
frequency, were fertile, and exhibited normal size and weight.
Cohorts of male and female mice composed of 9 to 16 mice per
genotype and gender were used. Mice expressing green fluores-
cent protein (GFP) in osteocytes (DMP1-GFP) were provided by
Dr David W. Rowe and were maintained as homozygous (14).
Mice were fed a regular diet (Harlan/Teklad), had ad libitum
water, and were maintained on a 12-hour light, 12- hour dark
cycle (7).All animal protocolswere approvedby the Institutional
Animal Care andUseCommittee at IndianaUniversity School of
Medicine.
Quantification of bone turnover markers
Bloodwas collectedmonthly by facial vein bleeding into hep-
arinized tubes, and plasma was separated from blood cells by
centrifugation at 1500g for 10minutes. C-telopeptide fragments
of type I collagen (CTX)weremeasured using anELISA (Ratlaps
EIA; Immunodiagnostic Systems). Alkaline phosphatase was
measured using the AMP buffer (Randox AP 3802) method on
aRandoxDaytona analyzer (Randox Laboratories Limited) (7).
BMD and microcomputed tomography
measurements
Total, femoral, and spine BMD was determined by dual-en-
ergy x-ray absorptiometry using a PIXImus II densitometer (GE
Medical Systems, Lunar Division), as previously described (6).
Mice were anesthetized via inhalation of 2.5% isoflurane (Iso-
Flo; Abbott laboratories) mixed with O2 (1.5 L/min). For mi-
crocomputed tomography (micro-CT) analysis, bones were dis-
sected, cleanedof soft tissue, stored in 70%ethanol, and scanned
at 6-"m resolution (Skyscan 1172; SkyScan), as previously de-
scribed (6, 7).
Bone formation rate and tartrate-resistant acid
phosphatase staining
Mice were injected with calcein and alizarin red to allow for
dynamic histomorphometric measurements, as previously pub-
lished (7). Femora were fixed in neutral buffer formalin and cut
at the midshaft. The distal half of the femur was embedded in
methyl metacrylate, and unstained sections were analyzed using
the OsteoMeasure high-resolution digital video system (Osteo-
Metrics, Inc) attached to an Olympus BX51TRF microscope
(OlympusAmerica Inc).Onlymeasurements on the endocortical
surface were done because by 5 month of age, the action of PTH
receptor signaling on the periosteal surface had subsided and the
fluorochrome labels on cancellous bone are very intricate, pre-
cluding accuratemeasurement of the bone formation rate (BFR).
The proximal half of the femur was decalcified, embedded in
paraffin, and sections were stained for tartrate-resistant acid
phosphatase (TRAPase) and counterstained with toluidine blue
to visualize osteoclasts, as previously described (15). Sections
were viewedon aLeitzDMRXEmicroscope (LeicaMikroskopie
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und SystemGmbH). Images were captured using a SPOT digital
camera (Diagnostic Instruments, Inc).
Ex vivo bone organ culture and in vitro cell culture
Calvarial bones, femur and tibia were harvested from
5-month old DCR!/! mice and littermate WT controls, main-
tained in #-MEM containing 10% fetal bovine serum for 24
hours. For osteocyte-enriched bone preparations, tibias were
harvested from 5-month-old mice, bone marrow cells were
flushed out, and bones were subjected to serial digestions with
collagenase and EDTA, as previously published (16). Sost ex-
pression was 1.5- and 2.4-fold higher in digested WT and
DCR!/! bones, respectively, demonstrating osteocyte enrich-
ment. Bones were treated with PTH (100nM) or vehicle for 4
hours, and mRNA was then isolated. Calvarial cells obtained
from 1-month-old C57BL/6 mice were cultured to reach conflu-
ence, and thenmediumwith ascorbic acid (50"g/mL)was added
for 5 to 6 days, changing half of the medium every 2 to 3 days,
as previously described (2). Cells were then treated with PTH
(100nM), dibutyryl cAMP (DBA; 1mM) or vehicle for 4 hours.
Figure 1. Deletion of the DCR progressively corrects the high resorption induced by PTH receptor signaling in osteocytes in male and female mice.
A, Longitudinal analysis of CTX for the male cohort from 1 to 5 months. Symbols represent the means " SD of 7 to 16 mice per group. #, P # .05
for DMP1-caPTHR1 vs DMP1-caPTHR1;DCR!/! CTX levels at 1 and 5 months. Bars represent means " SD of 7 to 16 mice per group. *, P # .05
DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and DCR!/!, respectively, by two-way ANOVA. B, Representative images of cross-sections of
the femoral midshaft of 5-month-old males stained for TRAPase/toluidine blue. Bars indicate 50 "m. C, Longitudinal analysis of CTX for the female
cohort from 1 to 5 months. Symbols represent the means " SD of 7 to 16 mice per group. #, P # .05 DMP1-caPTHR1 vs DMP1-caPTHR1;DCR!/!
CTX levels at 1 and 5 months. Bars represent means " SD of 7 to 16 mice per group. *, P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT
and DCR!/!, respectively; #, P # .05 for conditions connected by the lines, by two-way ANOVA.
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Osteoblasts and osteocytes were isolated from calvarial bones of
9- to 11-day-old DMP1-GFP mice in which osteocytes are la-
beled with GFP, as previously published (6, 14). Calvarial bones
were subjected to 9 sequential 20-minute digestions with a mix-
ture of trypsin/EDTA/collagenase P (17). The first digestion was
discarded, and cells from all other digestions were pulled and
immediately subjected to fluorescence-activated cell sorting
(FACS), as previously reported (6, 18).GFP-positive (osteocytes)
andGFP-negative (osteoblasts) cells were cultured separately on
plates coated with collagen I as described earlier (19, 20) for 48
hours and treated with PTH (100nM) or vehicle for 4 hours.
Gene expression analysis by quantitative PCR
Calvariae from 1- or 5-month-old mice were cleaned and
frozen immediately in liquid nitrogen and stored at!80°C until
RNAisolation.Culturedbonesor cellswere rinsedwithPBS, and
RNA was immediately isolated. Total RNA was purified using
Trizol reagent (Invitrogen) according to the manufacturer’s in-
structions.Gene expressionwasanalyzedbyquantitativePCRas
previously described using primer probe sets from Applied Bio-
systems or from Roche Applied Science (6, 7). Relative mRNA
expression levels were normalized to the housekeeping genes
ribosomal protein S2 (ChoB) or glyceraldehyde-3-phosphate de-
hydrogenase (Gapdh) using the cycle threshold ($Ct) method.
Statistical analysis
Data were analyzed using SigmaStat (SPSS Science). Differ-
ences between group means were evaluated using two-way
ANOVA, followed by pairwise multiple comparisons using Stu-
dent-Newman-Keuls method. All values are reported as the
mean " SD.
Figure 2. Removal of the DCR does not affect the increase in BMD exhibited by DMP1-caPTHR1 mice. Longitudinal analysis of total, spinal, and
femoral BMD in both males (A) and females (B) at 1-month intervals up to 5 months of age. Symbols are means " SD (n % 7–19 mice per group).
No significant differences were detected among phenotypes.
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Results
Deletion of the DCR gradually corrects high
resorption and remodeling driven by PTH receptor
signaling in osteocytes
To investigate whether direct regulation of the Rankl
gene by PTH in osteocytes is required to stimulate bone
resorption, we examined resorption in DMP1-caPTHR1
mice crossed with knock-in mice lacking the DCR of the
Rankl gene regulated by PTH. Longitudinal analysis of
circulating CTX in male mice showed the expected high
resorption in growing mice of all genotypes that progres-
sively decreased to plateau at 3 to 5 months of age (Figure
1A). Resorption was significantly higher (approximately
100%) in DMP1-caPTHR1 mice and nonsignificantly
lower (between 15% and 30%) in DCR!/! mice vs WT
littermates across all ages. CTX in compound DMP1-
caPTHR1;DCR!/!mice was similar to DMP1-caPTHR1
mice at 1 and 2 months of age, but deletion of the DCR
gradually corrected the increased resorption exhibited by
DMP1-caPTHR1mice. By 3 months of age, CTX in com-
pound mice was significantly lower compared with
DMP1-caPTHR1mice (and50%higher thanWT), andby
5 months, it was undistinguishable from WT mice. Al-
though accurate measurements of osteoclast numbers for
DMP1-caPTHR1mice at this age are not possible, TRAPase
staining of cross-sections at the femoral midshaft show
that the abundant TRAPase staining exhibited by
DMP1-caPTHR1 bones is decreased in compound mice
lacking the DCR (Figure 1B).
Similar results were found in the longitudinal analysis of
CTXforfemalemice.Resorptionwashigh inthefirst2months
for all genotypes (Figure 1C). As found for male mice, resorp-
tioninDMP1-caPTHR1femalemicewasabout70%to100%
higher comparedwithWTlittermatesandshowedanonsignif-
icantdecrease(7%–13%)inDCR!/!micecomparedwithWT
at all ages.DMP1-caPTHR1;DCR!/! femalemice had similar
CTXlevels toDMP1-caPTHR1miceforthefirst2months,but
at3months,DMP1-caPTHR1;DCR!/! femalemiceshoweda
significant decrease in CTX compared with DMP1-caPTHR1
mice. CTX remained significantly lower in compound
mice at 4 and5monthsof age, but in contrast tomalemice,
it never reached WT levels. Thus, in female mice, the ab-
sence of DCR reduced but did not completely normalize
the high resorption induced by the DMP1-caPTHR1
transgene.
DCRdeletion did not affect the high BMDexhibited by
male or femaleDMP1-caPTHR1mice. Thus, longitudinal
BMD analysis revealed no significant changes in total,
femoral, or spinal BMD in compound DMP1-caPTHR1;
DCR!/! compared with DMP1-caPTHR1 littermate
male or female mice (Figure 2, A and B). However, mi-
cro-CT analysis of femoral bone revealed decreased bone
volume in compound male mice compared with DMP1-
caPTHR1 littermates (Tables 1and2andFigure3A).Both
bone volume over tissue volume (BV/TV) in the distal fe-
mur and bone area over tissue area (BA/TA) in the femoral
midhsaft were lower inDMP-caPTHR1micewith deleted
DCR. Dynamic histomorphometric analysis showed that
the decreased bone volume in the compound mice was
accompanied by a reduced BFR on the endocortical sur-
face of the femur compared with single DMP1-caPTHR1
transgenic mice (Table 3 and Figure 3B). This effect was
due to combined reduction in the numbers of osteoblasts
coveringbone surfacesmineralizing surfaceoverbone sur-
face (MS/BS) and in the activity of osteoblast teams (min-
eral apposition rate [MAR]). Moreover, although intra-
cortical bone formation could not be quantified, also due
to the convoluted fluorochrome incorporation, deletionof
the DCRmarkedly decreased the amount and intensity of
fluorescent labels (Figure 3B).
Consistent with these effects on CTX and BFR, circu-
lating levels of the osteoblastmarker alkaline phosphatase
were elevated in5-month-oldDMP1-caPTHR1malemice
Table 1. Micro-CT Analysis of Distal Femur in Male
Micea
Genotype BV/TV, %
WT 27.37 " 3.05
DMP1-caPTHR1 58.37 " 10.37b
DCR!/! 31.01 " 0.48
DMP1-caPTHR1;DCR!/! 46.07 " 10.86b,c
a Data from 5-month-old male mice are presented. Bone volume over
tissue volume (BV/TV) values are means " SD of 4 to 10 mice per
group.
b P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and
DCR!/!, respectively.
c P # .05 DMP1-caPTHR1 vs. DMP1-caPTHR1;DCR!/!, by two-way
ANOVA.
Table 2. Micro-CT Analysis of Femoral Midshaft in
Male Micea
Genotype BA, mm2 TA, mm2 BA/TA, %
WT 0.85 " 0.06 1.96 " 0.22 43.34 " 3.68
DMP1-
caPTHR1
2.52 " 0.28b 3.03 " 0.15b 83.29 " 6.69b
DCR!/! 0.91 " 0.06 2.04 " 0.22 44.88 " 1.98
DMP1-
caPTHR1;
DCR!/!
2.55 " 0.63b 3.38 " 0.39b 75.04 " 12.08b,c
a Data from 5-month-old male mice are presented. Bone area (BA),
tissue area (TA), and bone area over tissue area (BA/TA) values are
means " SD of 4 to 10 mice per group.
b P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and
DCR!/!, respectively.
c P # .05 DMP1-caPTHR1 vs. DMP1-caPTHR1;DCR!/!, by two-way
ANOVA.
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Figure 3. Removal of the DCR blunts the increased bone remodeling induced by PTH receptor activation in osteocytes. A, Representative micro-
CT images of distal femur and femoral midshaft of 5-month-old male mice. B, Representative images of unstained cross-sections of the femoral
midshaft. Arrows point at the endocortical surface. C, Alkaline phosphatase was measured in plasma from 5-month-old male and female mice for
all groups. Bars represent means " SD of 7 to 11 male mice and 10 to 15 female mice per group. D, Bone material density was determined by
micro-CT analysis of femoral bone from 5-month-old mice. Bars represent the means" SD of 4 to 7 male mice and 4 female mice per group. *, P# .05
DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and DCR!/!, respectively; #, P# .05 for conditions connected by the lines, by two-way ANOVA.
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and were reduced to WT levels in compound DMP1-
caPTHR1;DCR!/!male mice (Figure 3C). A reduction in
alkaline phosphatase was also found in female mice, al-
though, similar to CTX levels, alkaline phosphatase levels
in compound femalemice did not reachWTvalues (Figure
3C). In addition, DMP1-caPTHR1 bones exhibited lower
material density, an index of tissue mineralization that
typically is reduced in conditions of highbone remodeling,
and this effectwas partially corrected inDMP1-caPTHR1
male mice lacking the DCR (Figure 3D). Consistent with
the findings for CTX and alkaline phosphatase, the de-
crease in bone material density exhibited by DMP1-
caPTHR1 mice was also prevented to a lesser extent in
female than inmalemice. Furthermore,micro-CTanalysis
demonstrate that deletionof theDCR inDMP1-caPTHR1
female mice does not reduce bone volume in either the
distal femur or the femoral midshaft (Tables 4 and 5),
confirming that the effect of theDCRdeletion isweaker in
females. Indeed, bone volume at both sites is increased in
female compound mice, suggesting that a mild reduction
in resorption induced by theDCRdeletion is not sufficient
to inhibit bone formation coupled to resorption, and bone
is preserved.
PTH receptor signaling upregulates Rankl
expression in osteocytes in vivo, ex vivo, and in
vitro
The increased resorption exhibited by DMP1-caPTHR1
malemicewasaccompaniedbyhighRanklmRNAinbone
at1and5monthsof age (Figure4A). In compoundDMP1-
caPTHR1;DCR!/! mice, Rankl expression closely
matched the described effects on bone resorption. Thus,
Rankl expression levels were similar to DMP1-caPTHR1
mice at 1 month of age and reduced to WT levels at 5
months. A similar pattern of expression was observed for
M-Csf (Figure 4B), a survival factor for osteoclast pro-
genitors and mature osteoclasts previously shown to be
upregulated by RANKL in cultured RAW 264.7 macro-
phage cells (21). In addition, the increased expression in
bone of TRAPase and cathepsin K, genes expressed in
osteoclasts, exhibited by DMP1-caPTHR1 mice was de-
creased to WT levels in compound DMP1-caPTHR1;
DCR!/! male mice (Figure 4C). Similar regulation of
Rankl, M-Csf, Trapase, and cathepsin K was found in
bones from 5-month-old female mice of the 4 genotypes
(Figure 4D). These results demonstrate that PTH receptor
signaling in osteocytes regulates Rankl, as well as M-Csf
and osteoclastic genes, through the DCR in vivo.
Deletion of the DCR also blunted the increase inRankl
expression induced by PTH ex vivo (Figure 5, A and B).
Thus, PTH increased Rankl and decreased Sost andOpg
expression in calvaria organ cultures established fromWT
mice. In contrast, the upregulation of the Rankl gene was
eliminated in bones fromDCR!/!mice, whereas Sost and
Opg expression was regulated by PTH to the same extent
in DCR!/! and WT bones. Similar regulation of Rankl
expression by PTH in WT but not in DCR!/! mice was
Table 3. Dynamic Histomorphometric Analysis of
Endocortical (Ec.) Bone at the Femoral Midshaft in Male
Micea
Genotype
Ec. MAR,
"m/d
Ec. MS/BS,
%
Ec. BFR,
"m3/"m2/day
WT 0.75 " 0.28 57.89 " 12.52 0.44 " 0.22
DMP1-
caPTHR1
1.03 " 0.25b 53.62 " 10.77 0.57 " 0.25
DCR!/! 0.68 " 0.26 48.34 " 7.56 0.33 " 0.16
DMP1-
caPTHR1;
DCR!/!
0.52 " 0.21c 37.95 " 7.75b,c 0.23 " 0.10c
a Data from 5-month-old male mice are presented. Mineral apposition
rate (MAR), mineralizing surface over bone surface (MS/BS), and bone
formation rate (BFR) values are means " SD of 4 to 10 mice per group.
b P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and
DCR!/!, respectively.
c P # .05 DMP1-caPTHR1 vs. DMP1-caPTHR1;DCR!/!, by two-way
ANOVA.
Table 4. Micro-CT Analysis of Distal Femur in Female
Micea
Genotype BV/TV, %
WT 32.37 " 0.89
DMP1-caPTHR1 89.26 " 0.79b
DCR!/! 35.64 " 1.72
DMP1-caPTHR1;DCR!/! 92.49 " 0.36b,c
a Data from 5-month-old female mice are presented. Values are
means " SD of 4 mice per group.
b P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and
DCR!/!, respectively.
c P # .05 DMP1-caPTHR1 vs. DMP1-caPTHR1;DCR!/!, by two-way
ANOVA.
Table 5. Micro-CT Analysis of Femoral Midshaft in
Female Micea
Genotype BA, mm2 TA, mm2 BA/TA, %
WT 0.81 " 0.04 1.80 " 0.06 45.17 " 1.28
DMP1-
caPTHR1
3.52 " 0.17b 3.51 " 0.19b 92.21 " 0.98b
DCR!/! 0.93 " 0.06 1.87 " 0.08 49.72 " 1.62
DMP1-
caPTHR1;
DCR!/!
3.59 " 0.19b 3.82 " 0.19b 94.03 " 0.64b,c
a Data from 5-month-old female mice are presented. Bone area (BA),
tissue area (TA), and bone area over tissue area (BA/TA) values are
means " SD of 4 mice per group.
b P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and
DCR!/!, respectively.
c P # .05 DMP1-caPTHR1 vs. DMP1-caPTHR1;DCR!/!, by two-way
ANOVA.
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observed in organ cultures of femur or tibia (Figure 5B).
Furthermore, PTH increased Rankl expression in organ
cultures established from tibial bones enriched in osteo-
cytes fromWTbut not fromDCR!/!mice, demonstrating
that PTH upregulates Rankl expression in osteocytes ex
vivo through the DCR.
Figure 4. Deletion of the DCR corrects the elevated expression of Rankl and M-Csf in adult, but not in young, DMP1-caPTHR1 mice. A–C,
Quantitative PCR analysis of mRNA transcripts in calvariae from 1- and 5-month-old male mice. Bars represent means " SD of 3 to 5 mice per
group. D, Gene expression in calvaria from 5-month-old female mice. Bars represent means " SD of 5 mice per group. Results are expressed
relative to the housekeeping gene ribosomal protein S2 (ChoB). *, P # .05 DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and DCR!/!,
respectively, by two-way ANOVA.
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Figure 5. PTH receptor signaling modulates Rankl expression in osteocytes in vitro and ex vivo through direct regulation of the Rankl gene. The
expression of the indicated genes was measured by quantitative PCR. Results are expressed relative to Gapdh. A and B, Ex vivo bone organ
cultures were cultured overnight and treated with vehicle or PTH for 4 hours. Bars represent mean " SD of 3 to 5 mice per genotype. *, P # .05
DMP1-caPTHR1 or DMP1-caPTHR1;DCR!/! vs WT and DCR!/!, respectively; #, P # .05 for conditions connected by the lines, by two-way ANOVA.
C, Primary cultures of calvaria cells obtained from newborn C57BL/6 mice were treated with vehicle (veh), PTH, or DBA for 4 hours. Bars represent
mean " SD of 5 independent wells per treatment. *, P # .05 vs vehicle-treated cultures, by one-way ANOVA. D, Primary osteoblasts (OB) and
osteocytes (OT) were isolated by FACS, and the expression of the indicated genes was quantified immediately after sorting. Bars represent mean "
SD of 2 independent wells and duplicate measurements per treatment. *, P # .05 PTH vs vehicle-treated cultures by two-way ANOVA; #, P # .05
for OT vs OB, by two-way ANOVA (for Rankl) or t test (for Pthr1).
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PTH also increasedRankl expression in differentiating
primary cultures of mouse calvarial cells (Figure 5C). A
similar increase was induced by addition of the stable an-
alog of cAMP, DBA. We previously demonstrated that
these cultures contain osteocytes, as evidenced by a time-
dependent increase in Sost transcripts and the presence of
sclerostin-positive cells (2).Consistentwith these previous
findings, SostmRNAwas readily detectable after 6days of
culture, andadditionofPTHorDBAfor4hoursmarkedly
decreased Sost expression. PTH and DBA also decreased
expression ofOpg and increased the expression of Fgf23,
genes known to be expressed in both osteocytes and
osteoblasts.
To discern directly between effects of the hormone on
osteoblasts vs osteocytes, authentic cells isolated from cal-
varial bones of DMP1-GFP mice by controlled enzymatic
digestions followed by FACS were maintained in culture
and treated with PTH (Figure 5D). Osteocytes (GFP-pos-
itive cells) expressed approximately double the amount of
RANKL transcripts than osteoblasts
(GFP-negative cells) (1.8- " 1.2-
fold). PTH stimulated Rankl ex-
pression in both osteoblasts and os-
teocytes, although the degree of
stimulation was higher in osteocytes
than in osteoblasts. Thus, PTH in-
creasedRankl expression by 8.88-"
1.2-fold in osteoblasts and by 12.2- "
1.9-fold in osteocytes. This differ-
ence could be explained potentially
by the fact that osteocytes expressed
3.4-"0.78-foldmorePthr1 thanos-
teoblasts. As expected, only osteo-
cytes exhibit transcripts for Sost, and
PTH eliminated Sost expression.
Discussion
It has long been recognized that PTH
increases osteoclast production and
resorption by upregulating the Rankl
gene in cells of the osteoblastic lin-
eage. However, the precise differen-
tiation stage of the PTH target cell
has been undefined. Recent evidence
demonstrates that PTH regulates os-
teocytic gene expression (1), that os-
teocytes are an important source of
RANKL (22), and that deletion of
the PTH receptor from osteocytes
decreases Rankl expression (23).
The findings of the current study
demonstrate that resorption induced by PTH receptor sig-
naling in skeletally mature mice requires direct regulation
of theRanklgene inosteocytesmediatedby theDCRof the
gene (Figure 6). Furthermore, we show that PTH regulated
Rankl expression in osteocyte-containing primary cultures of
calvarialcells, in isolatedmurineosteocytes,andinexvivobone
organ cultures in a DCR-dependent manner.
In contrast to skeletally mature mice, neither CTX nor
Rankl transcripts were affected by deletion of the DCR
in 1- to 2-month-old mice, indicating that resorption
and Rankl expression in the growing skeleton of
DMP1-caPTHR1mice are regulated by other factors that
do not require the DCR. Osteocyte-derived gp130 cyto-
kines, such as IL-6, IL-11, or oncostatin M could be in-
volved in the stimulation of Rankl, because they are ex-
pressed by osteocytes and PTH has been shown to
stimulate at least IL-6 and IL-11 expression in osteoblastic
cells (24–28). In addition, PTHupregulates the expression
Figure 6. Osteocytic PTH receptor-driven resorption is controlled by the DCR of the Rankl gene
in the mature skeleton. PTHR1 signaling through cAMP acts directly on the DCR to control Rankl
expression and resorption in the mature murine skeleton. Stimulation of Rankl expression and
resorption in the growing skeleton might result from increased gp130 cytokine signaling through
signal transducer and activator of transcription 3 (STAT3) response elements or from increased
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) mediated by the vitamin D3 receptor (VDR), or both.
PKA, protein kinase A; CREB, cAMP response element-binding protein.
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of the common signal transducer gp130 in cells of the
stromal osteoblastic lineage (27, 29). This evidence raises
the possibility that elevated expression of ligands or re-
ceptors of this family of cytokines could mediate the in-
crease in Rankl expression. In addition, compared with
littermate controls, DMP1-caPTHR1 mice exhibit higher
circulating levels of 1,25-dihydroxyvitamin D3 (4, 6), an-
other recognized stimulator of Rankl gene transcription.
Most of the circulating products of collagen degrada-
tion (CTX) in growing mice (like our 1-month-old mice)
are expected to derive from osteoclast activity in cortical
bone, the so-called resorptive modeling (30). In contrast,
CTX in adult mice (like our 5-month-old mice) probably
represent osteoclast activity involved in bone remodeling,
towhich cancellous bone is amajor contributor. The basal
phenotypeofDCR!/!mice ismanifested in adult animals,
which exhibit reduced bone remodeling and a modest in-
crease in bone mass confined to the cancellous bone com-
partment (31). Together with this earlier evidence, our
findings showing an age-dependent effect of the DCR de-
letion on DMP1-caPTHR1 mice suggest that PTH recep-
tor signaling in osteocytes drives resorptive modeling in
the growing skeleton mainly through DCR-independent
stimulators of Rankl expression, such as IL-6–type cyto-
kines, whereas it stimulates resorption in cancellous bone
in the adult skeleton viaDCR-dependentmechanisms. Fu-
ture studies are required to identify the DCR-independent
mechanisms and bone compartments involved in resorp-
tion driven by PTH receptor signaling in the growing
skeleton.
Remarkably, in contrastwithour findings showing that
Rankl is equally stimulated in 1-month-old DMP1-
caPTHR1 mice regardless of whether DCR is deleted or
not, earlier studies showed that endogenous elevation of
PTH induced by calcium deficiency does not increase
Rankl expression in growing mice lacking the DCR (32).
The apparent discrepancy could be explained by the dif-
ferent ways of activating PTH receptor signaling. In the
paper byO’Brien and colleagues (32), endogenous PTH is
elevated systemically, thus affecting all PTH-responsive
cells, whereas in the current study, the PTH receptor is
activated only in osteocytes. Taken together, these find-
ings suggest that PTHactions in cells other thanosteocytes
are responsible for the Rankl increase with systemic ele-
vation of PTH in growingmice. In contrast, similar to our
study, Rankl expression induced by endogenous PTH el-
evation was not increased in adult mice lacking the DCR,
suggesting that osteocytes are the major contributors to
Rankl regulation by PTH in the mature skeleton.
We have previously shown that DMP1-caPTHR1mice
exhibit a consistent decrease in material density of about
10% compared with WT littermates (6, 33). This index
measured by micro-CT is indicative of tissue mineraliza-
tion and age of the mineral. Reduced values of bone ma-
terial density reveal accumulation of undermineralized
bone, which could result from an increased bone remod-
eling rate that does not give enough time for the new bone
to fully mineralize or from abnormal mineralization. We
have shown that further stimulation of resorption in the
DMP1-caPTHR1 mice decreased material density even
more. Conversely, treatment of DMP1-caPTHR1 mice
with bisphosphonates, which strongly inhibits resorption,
increased material density by 7.4% toward values found
in WT mice (33). In the current study, we found that de-
letionof theDCR,whichblocksonlyPTH-inducedRankl-
mediated resorption, also increases material density in
DMP1-caPTHR1 mice but to a lesser extent, by 3.7%.
Taken together, these pieces of evidence suggest that in the
DMP1-caPTHR1 mouse model, bone material density is
regulated by changes in resorption and that deletion of the
DCR decreases the rate of bone remodeling leading to
bone with higher levels of mineralization. Nevertheless,
decreasedmaterial density could result also fromdefective
mineralization, potentially caused by decreased 1,25-di-
hydroxyvitamin D3 or phosphate or to increased Fgf23.
However, 1,25-dihydroxyvitaminD3 is actually increased
and phosphate is not altered in DMP-caPTHR1 mice, as
reported earlier (4, 6). Although young DMP-caPTHR1
mice do exhibit increased Fgf23 that could have an impact
on bone mineralization (4), Fgf23 was practically unde-
tectable in bones from the 5-month-old mice used in this
study, of any genotype and gender. Therefore, we cannot
attribute the partial rescue of bone material density ob-
served in compound DMP1-caPTHR1;DCR!/! mice to
changes in Fgf23 expression.
RANKLandM-CSFare 2major factors that contribute
toosteoclastdifferentiationandmaturation. In thepresent
study, we found thatM-Csf mRNA levels in bone exhib-
ited a similar pattern of expression to Rankl transcripts.
Deletion of the DCR eliminates the ability of the PTH
receptor/cAMP pathway to increase Rankl expression.
Thus, the fact that at 5 months of age the expression of
both Rankl and M-Csf was reduced in DMP1-caPTHR1;
DCR!/! mice compared with single DMP1-caPTHR1
transgenicmice demonstrates thatM-Csf regulation is sec-
ondary to Rankl regulation. To our knowledge, this evi-
dence is the first in vivo demonstration of M-Csf regula-
tion by RANKL and is consistent with an earlier in vitro
study showing that RANKL augmented M-Csf produc-
tion in preosteoclastic cells (21). The regulation ofM-Csf
by RANKL appears counterintuitive, because M-Csf in-
creases the expression of the RANKL receptor RANK in
osteoclast precursors (34), suggesting that M-CSF is
needed for RANKL signaling. However, deletion of the
doi: 10.1210/en.2014-1046 endo.endojournals.org 2807
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 December 2014. at 17:55 For personal use only. No other uses without permission. . All rights reserved.
DCRreversesonly thePTHR1-inducedM-Csf expression,
demonstrating that basal levels of M-Csf are sufficient to
induce Rank expression and to allow the initial action of
PTH-stimulated osteocytic RANKL. RANKL/RANK sig-
naling in turn could induce higherM-Csf expression in a
positive feedback loop, stimulating osteoclastogenesis.
Furthermore, M-Csf is expressed not only in osteoclast
precursors but also in osteocytes (11, 12) suggesting that
RANKL (either membrane-bound or soluble form) could
upregulateM-Csf gene expression in osteoclast precursors
or in osteocytes. Future studies are required to determine
the cellular source ofM-Csf in osteocyte-driven resorption
induced by PTH receptor activation.
Despite themarked effects on resorptiondrivenbyPTH
receptor signaling in osteocytes, deletion of the DCR did
not affect BMD.DMP1-caPTHR1mice exhibit high bone
mass with elevated bone resorption and formation (6, 7,
33). Therefore, inhibition of resorption could lead to even
higher BMD. However, we found that bone volume is
reduced and alkaline phosphatase levels in the circulation
are decreased in compound DMP1-caPTHR1;DCR!/!
male mice compared with single transgenic DMP1-caPTHR1
mice. Moreover, bone formation on the endocortical sur-
face of the femoral midshaft is also reduced by deletion of
the DCR. Thus, the lack of an increase in BMD in the face
of reduced resorption is explained by concomitant re-
duced bone formation. These findings are consistent with
our earlier evidence demonstrating that bone formation
on the endocortical surface of DMP1-caPTHR1 mice re-
sults from a combination ofWnt-dependent increased os-
teoblast number and resorption-driven osteoblast activity
(33).
In contrast to our findings with male mice in which the
DCR deletion abolishes completely resorption at 5month
of age, DCR deletion has a weaker effect on resorption in
female DMP-caPTHR1 mice. This could be explained by
the higher bone remodeling rate exhibited by female com-
pared with male mice (2-fold higher CTX and 3-fold
higher alkalinephosphatase).Nevertheless, deletionof the
DCR reduces effectively the expression of Rankl, M-Csf,
and osteoclast markers in females, suggesting that given
enough time, compound femalemicewould exhibit a com-
plete reversal of resorption toward WT levels.
It is important to distinguish our study from that of
Leder and colleagues (35) inwhich daily injections of PTH
(1–34) combined with an anti-RANKL antibody in-
creased BMD more than PTH alone in humans. In our
study, activation of PTH receptor signaling is confined to
osteocytes, and consequently, the expression of Rankl is
increased (or not in the absence of DCR) solely in osteo-
cytes. Thus, deleting the DCR does not remove the effect
of PTH on Rankl expressed in other bone cells or the
effects of the hormone on other genes such as Sost and
Opg. Furthermore, PTH receptor signaling in the DMP1-
caPTHR1mice is activated in a continuousmanner, not in
an intermittent mode. These differences might explain the
failure of DCR deletion to further increase BMD in
DMP1-caPTHR1 mice. An experiment more comparable
to the study by Leder and colleagues (35) would be ad-
ministration of bisphosphonates to DMP1-caPTHR1
mice, which did increase BMD over the anabolic effect of
PTH receptor activation in osteocytes as we published
earlier (33).
In conclusion, resorption induced by PTH receptor sig-
naling in osteocytes requires direct regulation of theRankl
gene in osteocytes. Thus, whereas DCR-independent
mechanisms operate in the growing skeleton, DCR-de-
pendent, cAMP-activatedmechanismsmediate resorption
induced by PTH receptor signaling in the adult skeleton.
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